Efficacy of using a standard activity of 131I-MIBG therapy in patients with disseminated neuroendocrine tumours

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 5, 2010, Pages 904-912

  Navalkissoor, Shaunak ^a   Alhashimi, Dona M ^a   Quigley, Ann Marie ^a   Caplin, Martyn E ^a   Buscombe, John R ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

131I MIBG (meta iodobenzylguanidine); Efficacy; Neuroendocrine tumours; Therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HORMONE DETERMINATION; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCYTOPENIA; PHEOCHROMOCYTOMA; PROGRESSION FREE SURVIVAL; RADIOACTIVITY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TUMOR VOLUME;

3-IODOBENZYLGUANIDINE; DISEASE PROGRESSION; FEMALE; HORMONES; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 77952095664     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1326-3     Document Type: Article

References (22)

1. DM Wieland DP Swanson LE Brown WH Beierwaltes 1979 Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent J Nucl Med 20 155 158 1:STN:280:DyaE1M7ltlartg%3D%3D 430189 (Pubitemid 9129566)
2. AR Wafelman CA Hoefnagel RA Maes JH Beijnen 1994 Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry Eur J Nucl Med 21 545 559 10.1007/BF00173043 1:CAS:528:DyaK2cXmsV2msLk%3D 8082671
3. G Kaltsas M Korbonits E Heintz JJ Mukherjee PJ Jenkins SL Chew, et al. 2001 Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors J Clin Endocrinol Metab 86 895 902 10.1210/jc.86.2.895 1:CAS:528:DC%2BD3MXht1Knur0%3D 11158063 (Pubitemid 32207512)
4. V Rufini ML Calcagni RP Baum 2006 Imaging of neuroendocrine tumors Semin Nucl Med 36 228 247 10.1053/j.semnuclmed.2006.03.007 16762613 (Pubitemid 43817847)
5. AM Quigley JR Buscombe T Shah G Gnanasegaran D Roberts ME Caplin, et al. 2005 Intertumoural variability in functional imaging within patients suffering from neuroendocrine tumours. An observational, cross-sectional study Neuroendocrinology 82 3-4 215 220 10.1159/000092522 1:CAS:528: DC%2BD28Xkt12qtrs%3D 16601361
6. AJ McEwan B Shapiro JC Sisson WH Bierwaltes DM Ackery 1985 Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors Semin Nucl Med 15 132 153 10.1016/S0001-2998(85)80022-2 1:STN:280:DyaL2M3hvVyhtA%3D%3D 3890187
7. CA Hoefnagel 1994 Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours Eur J Nucl Med 21 561 581 1:CAS:528:DyaK2cXmsV2msLY%3D 7915987
8. KC Loh PA Fitzgerald KK Matthy PPB Yeo DC Price 1997 The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients J Endocrinol Invest 20 648 658 1:CAS:528:DyaK1cXhtFSrsLg%3D 9492103
9. JR Buscombe JB Cwikla ME Caplin AJ Hilson 2005 Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response Nucl Med Commun 26 969 976 10.1097/01.mnm.0000184941.06123.b9 1:CAS:528:DC%2BD2MXhtVOitLfP 16208174 (Pubitemid 41527286)
10. SD Safford RE Coleman JP Gockerman J Moore J Feldman MW Onaitis, et al. 2004 Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients Cancer 101 9 1987 1993 10.1002/cncr.20592 1:CAS:528:DC%2BD2cXhtVShtLfF 15455358 (Pubitemid 39425373)
11. BG Taal CA Hoefnagel RA Valdes Olmos H Boot JH Beijnen 1996 Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors J Clin Oncol 14 1829 1838 1:CAS:528:DyaK28Xkt1WksLo%3D 8656251 (Pubitemid 26185458)
12. JJ Mukherjee GA Kaltsas N Islam PN Plowman R Foley J Hikmat, et al. 2001 Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I-metaiodobenzylguanidine (131I-mIBG) Clin Endocrinol (Oxf) 55 47 60 10.1046/j.1365-2265.2001.01309.x 1:CAS:528:DC%2BD3MXmtVKgtbw%3D (Pubitemid 34204299)
13. J Bomanji KE Britton E Ur L Hawkins AB Grossman GM Besser 1993 Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine Nucl Med Commun 14 856 861 10.1097/00006231- 199310000-00004 1:STN:280:DyaK2c%2FltV2ntg%3D%3D 8233228 (Pubitemid 23302636)
14. AC Nwosu L Jones J Vora GJ Poston S Vinjamuri DM Pritchard 2008 Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours Br J Cancer 98 1053 1058 10.1038/sj.bjc.6604273 1:CAS:528:DC%2BD1cXjtlGkurs%3D 18283308 (Pubitemid 351399810)
15. MS Sywak JL Pasieka A McEwan G Kline O Rorstad 2004 131I-meta- iodobenzylguanidine in the management of metastatic midgut carcinoid tumors World J Surg 28 1157 1162 10.1007/s00268-004-7603-1 15490060 (Pubitemid 40109869)
16. Giovanella LC. Chromogranin A: a circulating neuroendocrine marker-biology, pathology, assay technology and clinical applications. Cisbio www.ria-cis.com/ressources/produits/00370%20CIS%20CHROMOGRANIN%20GB.pdf
17. SL Fielding MA Flower D Ackery JT Kemshead LS Lashford I Lewis 1991 Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study Eur J Nucl Med 18 308 316 10.1007/BF02285457 1:CAS:528:DyaK3MXkvVygsb8%3D 1936038
18. M Monsieurs B Brans K Bacher R Dierckx H Thierens 2002 Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans Eur J Nucl Med Mol Imaging 29 12 1581 1587 10.1007/s00259-002-0973-4 1:CAS:528:DC%2BD38XptFGisLc%3D 12458391 (Pubitemid 35435727)
19. IM Modlin I Latich M Zikusoka M Kidd G Eick AK Chan 2006 Gastrointestinal carcinoids: the evolution of diagnostic strategies J Clin Gastroenterol 40 572 582 10.1097/00004836-200608000-00003 16917396 (Pubitemid 44259760)
20. G Paganelli L Bodei D Handkiewicz Junak P Rocca S Papi M Lopera Sierra, et al. 2002 90Y-DOTA-D-Phe1-Tyr3-octreotide in therapy of neuroendocrine malignancies Biopolymers 66 393 398 10.1002/bip.10349 1:CAS:528: DC%2BD3sXislOqsbs%3D 12658726 (Pubitemid 36433534)
21. DJ Kwekkeboom WW de Herder BL Kam CH van Eijck M van Essen PP Kooij, et al. 2008 Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 26 2124 2130 10.1200/JCO.2007.15.2553 1:CAS:528:DC%2BD1cXms1Ort7s%3D 18445841
22. M Madsen D Bushnell ME Juweid Y Menda MS O'Dorisio T O'Dorisio, et al. 2006 Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model J Nucl Med 47 660 667 16595501 (Pubitemid 46768468)